Use of atorvastatin to inhibit hypoxia-induced myocardin expression

Chiung Zuan Chiu, Bao Wei Wang, Kou Gi Shyu

研究成果: 雜誌貢獻文章

14 引文 (Scopus)

摘要

Background Hypoxia induces the formation of reactive oxygen species (ROS), myocardin expression and cardiomyocyte hypertrophy. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to have both antioxidant and antihypertrophic effects. We evaluated the pathways of atorvastatin in repressing ROS and myocardin after hypoxia to prevent cardiomyocyte hypertrophy. Materials and methods Cultured rat neonatal cardiomyocytes were subjected to hypoxia, and the expression of myocardin and ROS were evaluated. Different signal transduction inhibitors, atorvastatin and N-acetylcysteine (NAC) were used to identify the pathways that inhibited myocardin expression and ROS. Electrophoretic motility shift assay (EMSA) and luciferase assay were used to identify the binding of myocardin/serum response factor (SRF) and transcription to cardiomyocytes. Cardiomyocyte hypertrophy was assessed by 3H-proline incorporation assay. Results Myocardin expression after hypoxia was inhibited by atorvastatin, RhoA/Rho kinase inhibitor (Y27632), extracellular signal-regulated kinase (ERK) small interfering RNA (siRNA)/ERK pathway inhibitor (PD98059), myocardin siRNA and NAC. Bindings of myocardin/SRF, transcription of myocardin/SRF to cardiomyocytes, presence of myocardin in the nuclei of cardiomyocytes and protein synthesis after hypoxia were identified by EMSA, luciferase assay, confocal microscopy and 3H-proline assay and were suppressed by atorvastatin, Y27632, PD98059 and NAC. Conclusions Hypoxia in neonatal cardiomyocytes increases myocardin expression and ROS to cause cardiomyocyte hypertrophy, which can be prevented by atorvastatin by suppressing ROS and myocardin expression.
原文英語
頁(從 - 到)564-571
頁數8
期刊European Journal of Clinical Investigation
42
發行號5
DOIs
出版狀態已發佈 - 五月 2012

指紋

Cardiac Myocytes
Assays
Reactive Oxygen Species
Serum Response Factor
Hypertrophy
Acetylcysteine
Extracellular Signal-Regulated MAP Kinases
Transcription
Luciferases
Proline
Small Interfering RNA
Atorvastatin Calcium
Hypoxia
myocardin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
rho-Associated Kinases
Signal transduction
Confocal microscopy
Confocal Microscopy
Rats

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry
  • Biochemistry

引用此文

Use of atorvastatin to inhibit hypoxia-induced myocardin expression. / Chiu, Chiung Zuan; Wang, Bao Wei; Shyu, Kou Gi.

於: European Journal of Clinical Investigation, 卷 42, 編號 5, 05.2012, p. 564-571.

研究成果: 雜誌貢獻文章

Chiu, Chiung Zuan ; Wang, Bao Wei ; Shyu, Kou Gi. / Use of atorvastatin to inhibit hypoxia-induced myocardin expression. 於: European Journal of Clinical Investigation. 2012 ; 卷 42, 編號 5. 頁 564-571.
@article{e656665d89b449b7a84bd0e469fe4979,
title = "Use of atorvastatin to inhibit hypoxia-induced myocardin expression",
abstract = "Background Hypoxia induces the formation of reactive oxygen species (ROS), myocardin expression and cardiomyocyte hypertrophy. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to have both antioxidant and antihypertrophic effects. We evaluated the pathways of atorvastatin in repressing ROS and myocardin after hypoxia to prevent cardiomyocyte hypertrophy. Materials and methods Cultured rat neonatal cardiomyocytes were subjected to hypoxia, and the expression of myocardin and ROS were evaluated. Different signal transduction inhibitors, atorvastatin and N-acetylcysteine (NAC) were used to identify the pathways that inhibited myocardin expression and ROS. Electrophoretic motility shift assay (EMSA) and luciferase assay were used to identify the binding of myocardin/serum response factor (SRF) and transcription to cardiomyocytes. Cardiomyocyte hypertrophy was assessed by 3H-proline incorporation assay. Results Myocardin expression after hypoxia was inhibited by atorvastatin, RhoA/Rho kinase inhibitor (Y27632), extracellular signal-regulated kinase (ERK) small interfering RNA (siRNA)/ERK pathway inhibitor (PD98059), myocardin siRNA and NAC. Bindings of myocardin/SRF, transcription of myocardin/SRF to cardiomyocytes, presence of myocardin in the nuclei of cardiomyocytes and protein synthesis after hypoxia were identified by EMSA, luciferase assay, confocal microscopy and 3H-proline assay and were suppressed by atorvastatin, Y27632, PD98059 and NAC. Conclusions Hypoxia in neonatal cardiomyocytes increases myocardin expression and ROS to cause cardiomyocyte hypertrophy, which can be prevented by atorvastatin by suppressing ROS and myocardin expression.",
keywords = "Cardiomyocyte hypertrophy, Reactive oxygen species, Statins, Transcription",
author = "Chiu, {Chiung Zuan} and Wang, {Bao Wei} and Shyu, {Kou Gi}",
year = "2012",
month = "5",
doi = "10.1111/j.1365-2362.2011.02628.x",
language = "English",
volume = "42",
pages = "564--571",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Use of atorvastatin to inhibit hypoxia-induced myocardin expression

AU - Chiu, Chiung Zuan

AU - Wang, Bao Wei

AU - Shyu, Kou Gi

PY - 2012/5

Y1 - 2012/5

N2 - Background Hypoxia induces the formation of reactive oxygen species (ROS), myocardin expression and cardiomyocyte hypertrophy. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to have both antioxidant and antihypertrophic effects. We evaluated the pathways of atorvastatin in repressing ROS and myocardin after hypoxia to prevent cardiomyocyte hypertrophy. Materials and methods Cultured rat neonatal cardiomyocytes were subjected to hypoxia, and the expression of myocardin and ROS were evaluated. Different signal transduction inhibitors, atorvastatin and N-acetylcysteine (NAC) were used to identify the pathways that inhibited myocardin expression and ROS. Electrophoretic motility shift assay (EMSA) and luciferase assay were used to identify the binding of myocardin/serum response factor (SRF) and transcription to cardiomyocytes. Cardiomyocyte hypertrophy was assessed by 3H-proline incorporation assay. Results Myocardin expression after hypoxia was inhibited by atorvastatin, RhoA/Rho kinase inhibitor (Y27632), extracellular signal-regulated kinase (ERK) small interfering RNA (siRNA)/ERK pathway inhibitor (PD98059), myocardin siRNA and NAC. Bindings of myocardin/SRF, transcription of myocardin/SRF to cardiomyocytes, presence of myocardin in the nuclei of cardiomyocytes and protein synthesis after hypoxia were identified by EMSA, luciferase assay, confocal microscopy and 3H-proline assay and were suppressed by atorvastatin, Y27632, PD98059 and NAC. Conclusions Hypoxia in neonatal cardiomyocytes increases myocardin expression and ROS to cause cardiomyocyte hypertrophy, which can be prevented by atorvastatin by suppressing ROS and myocardin expression.

AB - Background Hypoxia induces the formation of reactive oxygen species (ROS), myocardin expression and cardiomyocyte hypertrophy. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to have both antioxidant and antihypertrophic effects. We evaluated the pathways of atorvastatin in repressing ROS and myocardin after hypoxia to prevent cardiomyocyte hypertrophy. Materials and methods Cultured rat neonatal cardiomyocytes were subjected to hypoxia, and the expression of myocardin and ROS were evaluated. Different signal transduction inhibitors, atorvastatin and N-acetylcysteine (NAC) were used to identify the pathways that inhibited myocardin expression and ROS. Electrophoretic motility shift assay (EMSA) and luciferase assay were used to identify the binding of myocardin/serum response factor (SRF) and transcription to cardiomyocytes. Cardiomyocyte hypertrophy was assessed by 3H-proline incorporation assay. Results Myocardin expression after hypoxia was inhibited by atorvastatin, RhoA/Rho kinase inhibitor (Y27632), extracellular signal-regulated kinase (ERK) small interfering RNA (siRNA)/ERK pathway inhibitor (PD98059), myocardin siRNA and NAC. Bindings of myocardin/SRF, transcription of myocardin/SRF to cardiomyocytes, presence of myocardin in the nuclei of cardiomyocytes and protein synthesis after hypoxia were identified by EMSA, luciferase assay, confocal microscopy and 3H-proline assay and were suppressed by atorvastatin, Y27632, PD98059 and NAC. Conclusions Hypoxia in neonatal cardiomyocytes increases myocardin expression and ROS to cause cardiomyocyte hypertrophy, which can be prevented by atorvastatin by suppressing ROS and myocardin expression.

KW - Cardiomyocyte hypertrophy

KW - Reactive oxygen species

KW - Statins

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=84859717095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859717095&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2011.02628.x

DO - 10.1111/j.1365-2362.2011.02628.x

M3 - Article

C2 - 22129233

AN - SCOPUS:84859717095

VL - 42

SP - 564

EP - 571

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 5

ER -